Insights into the future of gastric acid suppression

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 9, 2009, Pages 524-532

  DeVault, Kenneth R ^a   Talley, Nicholas J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BENATOPRAZOLE; BICARBONATE; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CLOPIDOGREL; EBROTIDINE; ESOMEPRAZOLE; FAMOTIDINE; GASTRIN; GASTRIN ANTAGONIST; GASTRIN RECEPTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; ILAPRAZOLE; LAFUTIDINE; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; POTASSIUM COMPETITIVE ACID BLOCKER; PROTON PUMP INHIBITOR; SPIROGLUMIDE;

BEDTIME DOSAGE; CALCIUM ABSORPTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYANOCOBALAMIN DEFICIENCY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ERADICATION THERAPY; EVENING DOSAGE; FOOD; FOOD DRUG INTERACTION; GASTRODUODENAL ULCER; GASTROESOPHAGEAL REFLUX; HEART FAILURE; HEART INFARCTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION RISK; INTERSTITIAL NEPHRITIS; LIVER TOXICITY; MONOTHERAPY; MORNING DOSAGE; NONHUMAN; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REIMBURSEMENT; REVIEW; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH PARIETAL CELL; STOMACH PH; SUDDEN DEATH;

ANTI-ULCER AGENTS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; PEPTIC ULCER; PROTON PUMP INHIBITORS;

EID: 69949084345     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.125     Document Type: Review

References (95)

1. Bell, N. J. & Hunt, R. H. role of gastric acid suppression in the treatment of gastrooesophageal reflux disease. Gut 33, 118-124 (1992).
2. Shin, J. M. & Sachs, G. Pharmacology of proton pump inhibitors. Curr. Gastroenterol. Rep. 10, 528-534 (2008).
3. Nebel, O. T., Fornes, M. F. & Castell, D. O. symptomatic gastroesophageal reflux: Incidence and precipitating factors. Am. J. Dig. Dis. 21, 953-956 (1976).
4. Devault, K. r. & Castell, D. O. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch. Intern. Med. 155, 2165-2173 (1995).
5. Bell, N. J., Burget, D., Howden, C. W., Wilkinson, J. & Hunt, R. H. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 51 (suppl. 1), 59-67 (1992).
6. Miner, P., Katz, P. O., Chen, Y. & sostek, M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: A five-way crossover study. Am. J. Gastroenterol. 98, 2616-2620 (2003).
7. Johnson, D. A. et al. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesopahgeal reflux disease. Aliment. Pharmacol. Ther. 22 129-134 (2005).
8. Xue, S., Katz, P. O., Banerjee, P., Tutuian, R. & Castell, D. O. Bedtime H2 lockers improve nocturnal gastric acid control in GerD patients on proton pump inhibitors. Aliment. Pharmacol. Ther. 15, 1351-1356 (2001).
9. Fackler, W. K., Ours, T. M., Vaezi, M. F. & Richter, J. E. Long-term effect of H2rA therapy on nocturnal gastric acid breakthrough. Gastroenterology 122, 625-632 (2002).
10. Dean, B. B., Gano, A. D. Jr, Knight, K., Ofman, J. J. & Fass, R. effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin. Gastroenterol. Hepatol. 2, 656-664 (2004).
11. Hatlebakk, J. G., Katz, P. O., Camacho-Lobato, L. & Castell, D. O. Proton pump inhibitors: Better acid control when taken before a meal than without a meal. Aliment. Pharmacol. Ther. 14, 1267-1272 (2000).
12. Hatlebakk, J. G., Katz, P. O., Kuo, B. & Castell, D. O. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment. Pharmacol. Ther. 12, 1235-1240 (1998).
13. Gunaratnam, N. T., Jessup, T. P., Inadomi, J. & Lascewski, D. P. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 23, 1473-1477 (2006).
14. Yuan, Y. et al. The proportion of patients who are free of reflux symptoms during the initial days of treatment with proton pump inbitors (PPis) in GerD trials: A meta-analysis [abstract]. Gastroenterology 134 (suppl. 1), s174 (2008).
15. Hellström, P. M. & Vitols, S. The choice of proton pump inhibitor: does it matter? Basic Clin. Pharmacol. Toxicol. 94, 106-111 (2004).
16. Pantoflickova, D., Dorta, G., Ravic, M., Jornod, P. & Blum, A. L. Acid inhibition on the first day of dosing: Comparison of four proton pump inhibitors. Aliment. Pharmacol. Ther. 17, 1507-1514 (2003).
17. Erah, P. O., Goddard, A. F., Barrett, D. A., Shaw, P. N. & Spiller, R. C. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother. 39, 5-12 (1997).
18. Gustavson, L. E. et al. effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob. Agents Chemother. 39, 2078-2083 (1995).
19. Debets-Ossenkopp, Y. J., Namavar, F. & MacLaren, D. M. effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 14, 353-355 (1995).
20. Figura, N., Crabtree, J. e. & Dattilo, M. In vitro activity of lansoprazole against Helicobacter pylori. J. Antimicrob. Chemother. 39, 585-590 (1997).
21. Gatta, L. et al. Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. J. Antimicrob. Chemother. 51, 439-442 (2003).
22. Laine, L. et al. esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: Results of three Us multicenter, double-blind trials. Am. J. Gastroenterol. 95, 3393-3398 (2000).
23. Gisbert, J., Domínguez-Munoz, A., Domínguez-Martin, A., Gisbert, J. L. & Marcos, S. esomeprazole-based therapy in Helicobacter pylori eradication: Any effect by increasing the dose of esomeprazole or prolonging the treatment? Am. J. Gastroenterol. 100, 1935-1940 (2005).
24. Rostom, A. et al. Prevention of NsAiD-induced gastroduodenal ulcers. Cochrane Database of systematic reviews, issue 4. Art. No. CD002296. doi:10.1002/14651858.CD002296 (2002).
25. Yeomans, N. D. et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression Trial: Ranitidine versus Omeprazole for NsAiD-associated Ulcer Treatment (AsTrONAUT) study Group. N. Engl. J. Med. 338 719-726 (1998).
26. Yeomans, N. et al. An evidence-based analysis of esomeprazole therapy versus placebo for the prevention of gastric or duodenal ulcers in at-risk continuous NsAiD users [Abstract]. Gastroenterology 126, A604 (2004).
27. Miner, P. B. et al. Pharmacokinetics of naproxen and esomeprazole in PN400, a single-tablet, multilayer formulation of enteric coated naproxen coupled with immediate-release esomeprazole [abstract]. Gastroenterology 136, T1972 (2009).
28. Niazi, M., Naucler, E. & Naesdal, J. A single capsule formulation of esomeprazole 40 mg and acetylsalicylic acid 325 mg compared with the monotherapies given separately: A single-dose bioequivalence study in healthy subjects [abstract]. Gastroenterology 136, w1021 (2009).
29. Andriulli, A. et al. High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: A multicenter, randomized study. Am. J. Gastroenterol. 103, 3011-3018 (2008).
30. Hunt, R. H. importance of pH control in the management of GerD. Arch. Intern. Med. 159, 649-657 (1999).
31. Richter, J. E. et al. efficacy and safety of esomeprazole compared with omeprazole in GerD patients with erosive esophagitis: A randomized controlled trial. Am. J. Gastroenterol. 96, 656-665 (2001).
32. scott, L. J., Dunn, C. J., Mallarkey, G. & Sharpe, M. esomeprazole: A review of its use in the management of acid-related disorders. Drugs 62, 1503-1538 (2002).
33. Castell, D. O. et al. esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am. J. Gastroenterol. 97, 575-583 (2002).
34. Labenz, J. et al. A randomized comparitive study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: The eXPO study. Aliment. Pharmacol. Ther. 21, 739-746 (2005).
35. Kim, K. A. et al. enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clin. Pharmacol. Ther. 72, 90-99 (2002).
36. Tanaka, M., Yamazaki, H., Hakusui, H., Nakamichi, N. & Sekino, H. Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of pantoprazole: A preliminiary study. Chirality 9, 17-21 (1997).
37. Mano, M. et al. Plasma direct injection highperformance liquid chromatographic method for simultaneously determining e3810 enantiomers and their metabolites by using flavoproteinconjugated column. J. Pharm. Sci. 85, 903-907 (1996).
38. Pai, V. G. et al. Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease. World J. Gastroenterol. 12, 6017-6020 (2006).
39. Pai, V. & Pai, N. randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease. World J. Gastroenterol. 13, 4100-4102 (2007).
40. Mansfield, P., Henry, D. & Tonkin, A. singleenantiomer drugs: Elegant science, disappointing effects. Clin. Pharmacokinet. 43, 287-290 (2004).
41. Wu, J., Vakily, M., Witt, G. & Mulford, D. TAK-390Mr vs. lansoprazole for maintenance of drug concentration above a threshold which corresponds to higher time at pH > 4 [abstract]. Am. J. Gastroenterol. 102, s124 (2007).
42. Sarma, P. et al. TAK-390Mr, a proton pump inhibitor (PPi) with a novel duel delayed release formulation is highly effective in the healing of erosive esophagitis: Data from two randomized controlled trials [abstract]. Gastroenterology 134, s1073 (2008).
43. Lee, R. D., Vakily, M., Wu, J. & Atkinson, S. The effect and timing of food on the pharmacokinetics and pharmacodynamics of TAK-390Mr (modified release): Evidence for dosing flexibility [abstract]. Am. J. Gastroenterol. 102, s145 (2007).
44. Periclou, A. P. et al. A comparative pharmacodynamic study of iY-81149 versus omeprazole in patients with gastroesophageal reflux disease. Clin. Pharmacol. Ther. 68, 304-311 (2000).
45. Galmiche, J. P. et al. Tentaprazole: A novel proton pump inhibitor with a prolonged plasma half-life: Effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment. Pharmacol. Ther. 19, 655-662 (2004).
46. Hunt, R. H. et al. effect of intragastric pH of a PPi with a prolonged plasma half-life: Comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am. J. Gastroenterol. 100, 1949-1956 (2005).
47. Thomson, A. B. et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: A randomized three-way crossover study. Aliment. Pharmacol. Ther. 23, 1179-1187 (2006).
48. +-ATPase in vitro and in vivo. Biochem. Pharmacol. 71, 837-849 (2006).
49. Hunt, R. H. et al. Predictable, prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment. Pharmacol. Ther. 28, 187-197 (2008).
50. Castell, D. review of immediate-release omeprazole for the treatment of gastric acid related disorders. Exp. Opin. Pharmacother. 6, 2501-2510 (2005).
51. santarus Zegerid® (omeprazole/sodium bicarbonate) US full prescribing information [online], http://www.zegerid.com/assets/ pdfs/prescribing_information.pdf (2008).
52. Castell, D., Bagin, R., Goldlust, B., Major, J. & Hepburn, B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 21 1467-1474 (2005).
53. Freston, J. W., Chiu, Y. L., Mulford, D. J. & Ballard, E. D. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment. Pharmacol. Ther. 17, 361-367 (2003).
54. Fandriks, L., Lönroth, H., Pettersson, A. & Vakil, N. Can famotidine and omeprazole be combined on a once-daily basis? Scand. J. Gastroenterol. 42, 689-694 (2007).
55. Chowers, Y. et al. PPi activity is optimized by vB101, a parietal cell activator [abstract]. Gastroenterology 134, A172 (2008).
56. Andersson, K. & Carlsson, E. Potassiumcompetitive acid blockade: A new therapeutic strategy in acid-related diseases. Aliment. Pharmacol. Ther. 108, 294-307 (2005).
57. Kahrilas, P. J. et al. A randomized, comparative trial of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin. Gastroenterol. Hepatol. 5, 1385-1391 (2007).
58. Dent, J. et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am. J. Gastroenterol. 103, 20-26 (2008).
59. MedicineNet.com famotidine/calcium carbonate/magnesium hydroxide - chewable [online] www.medicinenet.com/ famotidinecalcium_carbonatemagnesium_hydroxide/article.htm
60. Konturek, P. C. et al. studies on the cytoprotective and antisecretory activity of ebrotidine: A review. Arzeimittelforschung 47, 578-589 (1997).
61. Castillo, J. R., Torelló, J. & Hernandez, A. Liver injury caused by ebrotidine: A new example of the utility of the postmarketing surveillance. Eur. J. Clin. Pharmacol. 56, 187-189 (2000).
62. Hirakawa, N. et al. A novel histamine 2 (H2) receptor antagonist with gastroprotective activity: II. synthesis and pharmacological evaluation of 2-furfuryl-thio and 2-furfurylsulfinyl acetamide derivatives with heteroaromatic rings. Chem. Pharm. Bull. (Tokyo) 46, 616-622 (1998).
63. Hersey, S. J. & Sachs, G. Gastric acid secretion. Physiol. Rev. 75, 155-189 (1995).
64. Chen, D. et al. Altered control of gastric acid secretion in gastrin-cholecyctokinin double mutant mice. Gastroenterology 126, 476-487 (2004).
65. Beltinger, J. et al. effects of spiroglumide, a gastrin receptor antagonist, inhibits gastrin stimulated gastric acid secretion in humans [abstract]. Gut 54 (suppl. VII), A36 (2005).
66. Dunlop, J. CCK receptor antagonists. Gen. Pharmacol. 31, 519-524 (1998).
67. Scarpignato, C., Pelosini, I. & Di Mario, F. Acid suppression therapy: where do we go from here? Dig. Dis. 24, 11-46 (2006).
68. Iwase, K. et al. regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin. Gastroenterology 113 782-790 (1997).
69. Nishi, T., Makuuchi, H. & weinstein, W. M. Changes in gastric eCL cells and parietal cells after long-term administration of high-dose omeprazole to patients with Barrett's esophagus. Tokai J. Exp. Clin. Med. 30, 117-121 (2005).
70. Modlin, I. M., Lye, K. D. & Kidd, M. A 50-year analysis of 562 gastric carcinoids: Small tumor or larger problem? Am. J. Gastroenterol. 99, 23-32 (2004).
71. Kuipers, E. J. et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N. Engl. J. Med. 334, 1018-1022 (1996).
72. Malfertheiner, P. et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht III consensus report. Gut 56, 772-781 (2007).
73. min-/+ mouse model of familial adenomatous polyposis. Cancer Res. 61, 625-631 (2001).
74. Yang, Y. X. et al. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 133, 748-754 (2007).
75. Chowdhury, J. R., Berkowitz, J. M., Praissman, M. & Fara, J. W. effect of sulfated and non-sulfated gastrin and octapeptidecholecystokinin on cat gall bladder in vitro. Experientia 32, 1173-1175 (1976).
76. Geevasinga, N., Coleman, P. L., Webster, A. C. & Roger, S. D. Proton pump inhibitors and acute interstitial nephritis. Clin. Gastroenterol. Hepatol. 4, 597-604 (2006).
77. Laheij, R. J. F. et al. risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292, 1955-1960 (2004).
78. Gulmez, S. E. et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: A population-based case-control study. Arch. Intern. Med. 167, 950-955 (2007).
79. Dial, S., Delaney, J. A., Barkun, A. N. & Suissa, S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficileassociated disease. JAMA 294, 2989-2995 (2005).
80. Neal, R. K. et al. recent treatment with H2 antagonists, antibiotics and gastric surgery as risk factors for salmonella infection [abstract]. BMJ 308, 176 (1994).
81. Neal, K. R., Scott, H. M., Slack, R. C. & Logan, R. F. Omeprazole as risk factor for Campylobacter gastroenteritis: Case-control study. BMJ 312, 414-415 (1996).
82. Cobelens, F. G., Leentvarr-Kuijpers, A., Kleijnen, J. & Coutinho, R. A. incidence and risk factors of diarrhoea in Dutch travelers: Consequences for priorities in pre-travel health advice. Trop. Med. Int. Health 3, 896-903 (1998).
83. Yang, Y. X., Lewis, J. D., Epstein, S. & Metz, D. C. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296, 2947-2953 (2006).
84. Recker, R. R. Calcium absorption and achlorhydria. N. Engl. J. Med. 313, 70-73 (1985).
85. O'Connell, M. B. et al. effects of proton pump inhibitors on calcium carbonate absorption in women: A randomized crossover trial. Am. J. Med. 118, 778-781 (2005).
86. Marcuard, S. P., Albernaz, L. & Khazanie, P. G. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann. Intern. Med. 120, 211-215 (1994).
87. Conrad, M. E. & schade, S. G. Ascorbic acid chelates in iron absorption: a role for hydorcholoric acid and bile. Gastroenterology 55, 35-45 (1968).
88. Koop, H. & Bachem, M. G. serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J. Clin. Gastroenterol. 14, 288-292 (1992).
89. Us Food and Drug Administration. Update of Safety Review: Follow-up to the August 9, 2007, Communication about the Ongoing Safety Review of Omeprazole and Esomeprazole [online] http://www.fda.gov/Drugs/ DrugsafetyPostmarketDrugsafetyinformationforPatientsandProviders DrugsafetyinformationforHeathcareProfessionals/ucm072476.htm (2007).
90. Bhatt, D. L. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NsAiD use: A report of the American College of Cardiology Foundation Task Force on Clinical expert Consensus Documents. J. Am. Coll. Cardiol. 52, 1502-1517 (2008).
91. Pezalla, E., Day, D. & Pulliadath, I. initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors [letter]. J. Am. Coll. Cardiol, 52, 1038-1039 (2008).
92. Ho, P. M. et al. risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301, 937-944 (2009).
93. Juurlink, D. N. et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180, 713-718 (2009).
94. Simon, T. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
95. Shaheen, N. J. The burden of gastrointestinal and liver diseases, 2006. Am. J. Gastroenterol. 101, 2128-2138 (2006).